Characterization of Ba813 harbouring Bacillus cereus in patients with haematological malignancy and hospital environments at a medical centre in Japan

Journal of Medical Microbiology
Tetsuji AoyagiMistuo Kaku

Abstract

Introduction.Bacillus cereus harbouring Ba813, a specific chromosomal marker of Bacillus anthtacis, is found in patients with severe manifestations and causes nosocomial outbreaks.Aim. We assessed the genetic characteristics and virulence of Ba813(+) B. cereus in a hospital setting.Methodology. Three neutropenic patients with haematological malignancy developed B. cereus bacteraemia within a short period. Fifteen B. cereus were isolated from different sites in a haematology ward. A total of 18 isolates were evaluated for Ba813- and B. anthracis-related virulence, food poisoning-related virulence, genetic diversity, bacteria motility and biofilm formation.Results.Ba813(+) B. cereus was detected in 33 % (1/3) of patients and 66 % (9/15) of the hospital environment. The 18 strains were divided into 2 major clusters (clade 1 and clade 2), and 14 strains were classified into clade 1. All Ba813(+) strains, including four sequence types, were classified into clade 1/the cereus III lineage, which is most closely related to the anthracis lineage. Two strains belonging to clade 1/non-cereus III carried the B. anthracis-associated cap gene, but not Ba813. B. cereus, including Ba813(+) strains, had significantly lower prevalence of enterot...Continue Reading

References

Jun 1, 1989·Southern Medical Journal·D J WeberC A Thomann
Mar 26, 2004·Nature Reviews. Microbiology·Luanne Hall-StoodleyPaul Stoodley
Nov 18, 2004·Journal of Bacteriology·Fergus G PriestMartin C J Maiden
Feb 8, 2005·Journal of Clinical Microbiology·Maria V ElziThomas Bodmer
Sep 7, 2006·Journal of Clinical Microbiology·David SuePatricia P Wilkins
Sep 28, 2006·Investigative Ophthalmology & Visual Science·Michelle C CalleganSonia Senesi
Apr 24, 2007·Applied and Environmental Microbiology·Emilia GhelardiAmy C L Wong
Nov 27, 2007·Environmental Microbiology·Marie-Hélène GuinebretièrePaul De Vos
Nov 8, 2008·BMC Microbiology·Alex R HoffmasterPatricia P Wilkins
May 16, 2009·Internal Medicine·Reiki KurokiHiroshi Watanabe
Apr 9, 2010·Clinical Microbiology Reviews·Edward J Bottone
Aug 10, 2010·Nature Reviews. Microbiology·Daniel B Kearns
Oct 13, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T SasaharaY Hirai
Jun 21, 2011·Diagnostic Microbiology and Infectious Disease·Jiwei ZhangTakayuki Ezaki
Nov 1, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Nobuyuki ShimonoKoichi Akashi
Nov 15, 2011·FEMS Immunology and Medical Microbiology·Toshinobu HoriiHideji Yanagisawa
Jun 7, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Susan A DolanJames K Todd
Aug 10, 2013·The Journal of Hospital Infection·I K HoseinJ Bosanquet
Jan 5, 2017·New Microbes and New Infections·S TusgulS G Giulieri
May 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vincent C C ChengKwok-Yung Yuen
May 4, 2018·Molecular Biology and Evolution·Sudhir KumarKoichiro Tamura
Apr 20, 2019·Emerging Infectious Diseases·Reiko AkamatsuHideaki Higashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.